BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics; option exercised
Boehringer Ingelheim Pharmaceuticals Inc. entered into a collaboration with ViraTherapeutics GMBH to develop a next generation oncolytic virus platform based on ViraTherapeutics' lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) currently in preclinical development for solid cancers.
- Gene Therapy, Cell Therapy
- Includes M&A Option
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com